^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    onalespib (AT13387) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Br J Cancer
    Title:

    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

    Published date:
    12/09/2021
    Excerpt:
    ...disease stabilisation ≥24 weeks was observed in 7/22 (32%) evaluable patients including patients with BRCA-mutated ovarian cancers...Combining onalespib and olaparib was feasible and demonstrated preliminary evidence of anti-tumour activity.
    DOI:
    10.1038/s41416-021-01664-8